AQST - Aquestive Therapeutics nabs Fast Track designation for allergic reaction product

The U.S. FDA has granted Fast Track designation to Aquestive Therapeutics' (NASDAQ:AQST) AQST-109, its epinephrine-based candidate for the treatment of severe allergic reactions. Shares are up 14% in premarket trading. AQST-109 is different from other epinephrine products in that it is delivered via an oral film. Aquestive (AQST) expects to report top-line results from a phase 2 study comparing AQST-109 to an intramuscular injection of epinephrine in the first half of the year. Read why Seeking Alpha contributor Biologics considers Aquestive (AQST) a strong buy.

For further details see:

Aquestive Therapeutics nabs Fast Track designation for allergic reaction product